CytoMed Therapeutics Ltd
Research CytoMed Therapeutics Ltd (GDTC) on Bullrun: market cap USD 11.06M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGDTC
- ExchangeNASDAQ
- CountrySingapore
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 11.06M
- Financial periodQ4 2025
Valuation Snapshot
latest market cap is USD 11.06M.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 11.06M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 15.85M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 39.24M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 56.49M | n/a | n/a | n/a |
About CytoMed Therapeutics Ltd
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is CytoMed Therapeutics Ltd's market cap?
CytoMed Therapeutics Ltd's market capitalization is USD 11.06M.
What does CytoMed Therapeutics Ltd do?
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.